Publications by authors named "Hideki Matsushita"
Ther Apher Dial
April 2020
Article Synopsis
- Daprodustat is an oral medication aimed at treating anemia in patients with chronic kidney disease, specifically focusing on those undergoing hemodialysis and not using erythropoiesis-stimulating agents.
- In a 24-week clinical trial, 28 Japanese patients were given daprodustat starting at 4 mg daily, which successfully raised their hemoglobin levels from a baseline of 9.10 g/dL to the target range of 10.0 to 12.0 g/dL by week 8.
- Throughout the study, daprodustat maintained these hemoglobin levels without introducing any new safety issues among the participants.
Invest New Drugs
October 2015
Article Synopsis
- - Trametinib, a MEK1/MEK2 inhibitor, was tested in a clinical study for safety and efficacy in Japanese cancer patients, with one part assessing trametinib alone and another part assessing it in combination with gemcitabine.
- - In the solo treatment phase, doses of trametinib were tolerated with some responses but did not reach maximum toxicity; the combo phase saw some responses but was complicated by serious interstitial lung disease in several patients.
- - Overall, trametinib was found to be tolerable as a single agent, but its combination with gemcitabine presented greater risks, highlighting a need for careful monitoring in this treatment approach.
